Post-hoc analysis could give new life to the Alzheimer’s drug aducanumab

Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc analysis of the arrested trials EMERGE and ENGAGE could be enough to approve the drug. The aducanumab saga continues as an FDA panel determines whether a post-hoc analysis could be enough to approve the drug